NL-OMON55830已完成3 期
An Open-Label, Multicenter Study to Evaluate Long-Term Outcomes With ABT-450/Ritonavir/ABT-267 (ABT-450/r/ABT-267) and ABT-333 With or Without Ribavirin (RBV) in Adults With Genotype 1 Chronic Hepatitis C Virus (HCV) Infection (TOPAZ-I). - AbbVie M14-423
适应症
试验速览
- 阶段
- 3 期
- 状态
- 已完成
- 发起方
- AbbVie Ltd.
- 入组人数
- 21
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional
入排标准
- 年龄范围
- 18 至 99（—）
入选标准
- •1. Males and females at least 18 years old at screening
- •2. Females must be post-menopausal for more than 2 years or surgically
- •sterile or practicing acceptable forms of birth control
- •3. Chronic hepatitis C, genotype 1 infection
- •4. Males must be surgically sterile or agree to practice acceptable forms
- •of birth control
- •5. Screening laboratory result indicating HCV genotype 1 infection.
排除标准
- •1. Use of contraindicated medication within 2 weeks of dosing
- •2. Abnormal laboratory tests
- •3. Current or past clinical evidence of Child-Pugh B or C classification or
- •history of liver decompensation
- •4. Confirmed presence of hepatocellular carcinoma
- •5. History of solid organ transplant
研究者
相似试验
进行中（未招募）
不适用
An Open-Label, Multicenter Study to Evaluate Long-Term Outcomes with ABT-450/Ritonavir/ABT-267 (ABT-450/r/ABT-267) and ABT-333 With or Without Ribavirin (RBV) in Adults With Genotype 1 Chronic Hepatitis C Virus (HCV) InfectioChronic Hepatitis C InfectionMedDRA version: 17.0Level: PTClassification code 10008912Term: Chronic hepatitis CSystem Organ Class: 10021881 - Infections and infestationsEUCTR2014-001022-14-ITAbbVie Deutschland GmbH & Co. KG1,650
进行中（未招募）
1 期
An Open-Label, Multicenter Study to Evaluate Long-Term Outcomes with ABT-450/Ritonavir/ABT-267 (ABT-450/r/ABT-267) and ABT-333 With or Without Ribavirin (RBV) in Adults With Genotype 1 Chronic Hepatitis C Virus (HCV) InfectioChronic Hepatitis C InfectionMedDRA version: 17.1Level: PTClassification code 10008912Term: Chronic hepatitis CSystem Organ Class: 10021881 - Infections and infestationsEUCTR2014-001022-14-SEAbbVie Deutschland GmbH & Co. KG1,650
进行中（未招募）
1 期
An Open-Label, Multicenter Study to Evaluate Long-Term Outcomes with ABT-450/Ritonavir/ABT-267 (ABT-450/r/ABT-267) and ABT-333 With or Without Ribavirin (RBV) in Adults With Genotype 1 Chronic Hepatitis C Virus (HCV) InfectioEUCTR2014-001022-14-DKAbbVie Deutschland GmbH & Co. KG1,650
进行中（未招募）
1 期
An Open-Label, Multicenter Study to Evaluate Long-Term Outcomes with ABT-450/Ritonavir/ABT-267 (ABT-450/r/ABT-267) and ABT-333 With or Without Ribavirin (RBV) in Adults With Genotype 1 Chronic Hepatitis C Virus (HCV) InfectioEUCTR2014-001022-14-DEAbbVie Deutschland GmbH & Co. KG1,650
进行中（未招募）
1 期
An Open-Label, Multicenter Study to Evaluate Long-Term Outcomes with ABT-450/Ritonavir/ABT-267 (ABT-450/r/ABT-267) and ABT-333 With or Without Ribavirin (RBV) in Adults With Genotype 1 Chronic Hepatitis C Virus (HCV) InfectioEUCTR2014-001022-14-NLAbbVie Deutschland GmbH & Co. KG1,650